Inclusion Criteria:

- Patients with suspected diagnosis of acute myeloid leukemia or related precursor
neoplasm, or acute leukemia of ambiguous lineage (classified according to the World
Health Organization (WHO) classification)

- Age ≥ 18 years. There is no upper age limit.

- No prior chemotherapy* for leukemia except hydroxyurea to control hyperleukocytosis

- Signed written informed consent *prior therapy of a preceding myelodysplastic
syndrome or myeloproliferative neoplasm is allowed

Exclusion Criteria:

- Severe neurological or psychiatric disorder interfering with ability to give an
informed consent

- No consent for registration, storage and processing of the individual disease
characteristics and course as well as information of the family physician about study
participation.

- No consent for biobanking of patient's biological specimens and performance of
analyses on stored material.